BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29963041)

  • 1. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
    Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():1231. PubMed ID: 29963041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.
    Tacken PJ; Ginter W; Berod L; Cruz LJ; Joosten B; Sparwasser T; Figdor CG; Cambi A
    Blood; 2011 Oct; 118(15):4111-9. PubMed ID: 21860028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW; Ratner DM; Seeberger PH; Hacohen N
    Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
    Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
    J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
    Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
    Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
    Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
    Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
    Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
    Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation.
    Moris A; Nobile C; Buseyne F; Porrot F; Abastado JP; Schwartz O
    Blood; 2004 Apr; 103(7):2648-54. PubMed ID: 14576049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.
    Cohn L; Chatterjee B; Esselborn F; Smed-Sörensen A; Nakamura N; Chalouni C; Lee BC; Vandlen R; Keler T; Lauer P; Brockstedt D; Mellman I; Delamarre L
    J Exp Med; 2013 May; 210(5):1049-63. PubMed ID: 23569326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
    Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
    J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells.
    Engering A; Geijtenbeek TB; van Vliet SJ; Wijers M; van Liempt E; Demaurex N; Lanzavecchia A; Fransen J; Figdor CG; Piguet V; van Kooyk Y
    J Immunol; 2002 Mar; 168(5):2118-26. PubMed ID: 11859097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
    Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():990. PubMed ID: 29867967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
    Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
    J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.
    Tacken PJ; de Vries IJ; Gijzen K; Joosten B; Wu D; Rother RP; Faas SJ; Punt CJ; Torensma R; Adema GJ; Figdor CG
    Blood; 2005 Aug; 106(4):1278-85. PubMed ID: 15878980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.